Brief: Sunesis Pharmaceuticals, Viracta Therapeutics Announce Definitive Merger Agreement

Viracta Therapeutics

30/11/2020 12:34

Nov 30 (Reuters) - Sunesis Pharmaceuticals Inc  SNSS.O :
    * SUNESIS PHARMACEUTICALS AND VIRACTA THERAPEUTICS ANNOUNCE
DEFINITIVE MERGER AGREEMENT
    * SUNESIS PHARMACEUTICALS INC - COMBINED COMPANY EXPECTED TO
HAVE
APPROXIMATELY $120 MILLION CASH BALANCE FOLLOWING CLOSE OF
MERGER
    * SUNESIS PHARMACEUTICALS INC - LEADING INSTITUTIONAL
INVESTORS
COMMITTED A TOTAL OF $105 MILLION IN PRIVATE FINANCINGS WITH
VIRACTA
    * SUNESIS PHARMACEUTICALS INC - VIRACTA STOCKHOLDERS ARE
EXPECTED
TO OWN APPROXIMATELY 86% OF COMBINED COMPANY
    * SUNESIS PHARMA- REGISTRATION TRIAL FOR VIRACTA'S LEAD
PROGRAM IN
EPSTEIN-BARR VIRUS -POSITIVE LYMPHOMAS EXPECTED TO BEGIN IN
FIRST HALF OF 2021
    * SUNESIS PHARMACEUTICALS INC - COMBINED CO WILL BE LED BY
VIRACTA'S CURRENT MANAGEMENT TEAM

Source text for Eikon:  ID:nGNX8JJ0st 
Further company coverage:  SNSS.O 

 ((Reuters.Briefs@thomsonreuters.com;))